![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C:
A Pooled Analysis of Phase 2 and 3 Clinical Trials
|
|
|
Reported by Jules Levin
AASLD - The Liver Meeti ng of the American Associati on for the Study of Liver Diseases (AASLD), October 20-24, 2017, Washington, District of Columbia, United States
Graham R Foster1, Sarah Kopecky-Bromberg2, Yang Lei2, Roger Trinh2, Federico Mensa2
1Hepatology Unit, Queen Mary University of London, London, United Kingdom; 2AbbVie Inc., North Chicago, Illinois, United States
![1027171](../images/102817/102817-8/1027171.gif)
![1027172](../images/102817/102817-8/1027172.gif)
![1027173](../images/102817/102817-8/1027173.gif)
![1027174](../images/102817/102817-8/1027174.gif)
![1027175](../images/102817/102817-8/1027175.gif)
![1027176](../images/102817/102817-8/1027176.gif)
![1027177](../images/102817/102817-8/1027177.gif)
![1027178](../images/102817/102817-8/1027178.gif)
![1027179](../images/102817/102817-8/1027179.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|